#OtsukaHoldings

Phase 3 (VISIONARY) trial data for the IgA nephropathy treatment VOYXACT has been disclosed. Demonstrates a significant stabilization of eGFR over 24 months compared with placebo, withSafety profile comparable to placebo. Progress toward FDA sbLA submission in the U.S. continues.

The company discloses the status of its share buyback. It describes the type of shares to be acquired, the total amount, the acquisition period, and the method, reporting that share buyback is being conducted to maximize shareholder value.

Otsuka Holdings has upwardly revised its full-year consolidated earnings forecast for FY2026, projecting net sales of 2,725 billion yen (8.1% increase from previous forecast) and net income of 355 billion yen (33.8% increase). The interim dividend has been increased from 70 yen to 100 yen, and the annual dividend has been revised to 200 yen.

For the fiscal year ending December 2026, revenue reached 1.3323 trillion yen (12.8% increase), with midterm profit hitting 218.5 billion yen (24.3% increase), setting a new record. Segment performance was also strong, driven by the healthcare-related and Nutraceuticals segments.

The Company has revised its consolidated earnings forecast for the Fiscal Year ending December 2026, reflecting an upward revision of sales and profits driven by strong business performance. Factors such as robust medical-related businesses and adjustments related to delays in antibody drugs have influenced this revision, which is expected to surpass previous projections.

In the Phase 3 (VISIONARY) trial of VOYXACT for IgA nephropathy, 2-year eGFR improvement and stabilization of kidney function were achieved. Progress on FDA sBLA review and preparations for filings in various countries were reported.

Notice regarding the status of share buyback, including overview of the shares to be acquired, total number, acquisition period, and method.

Otsuka Pharmaceutical's subsidiary has announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab, demonstrating renal function preservation and progressing with approval application to the US FDA. There are no changes to the consolidated performance forecast for the fiscal year ending December 2026.

Otsuka Holdings has decided to conduct a share buyback on June 2, 2026. The buyback period is from May 1, 2026, to May 31, 2026, with the total amount undisclosed. Details regarding the purpose and impact of the buyback are provided.

Conducted treasury stock acquisition of 783,900 shares totaling 8,491,102,487 yen from April 1 to April 30, 2026.

Consolidated revenue for Q1 of the fiscal year ending December 2026 was JPY 630,342 million (an 8.2% increase year-over-year), and net income attributable to owners of the parent for the quarter was JPY 98,348 million (a 15.7% increase year-over-year).

On April 24, 2026, Otsuka Holdings disposed of 83,920 ordinary shares as restricted stock compensation at ¥11,090 per share, with a total amount of ¥930,672,800, and completed the payment procedures.